tetano
Editor, Senior Moderator
Am J Transplant
. 2022 Jul 16.
doi: 10.1111/ajt.17151. Online ahead of print.
An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: a randomized controlled trial (CVIM 4 study)
Jackrapong Bruminhent[SUP] 1 2 [/SUP], Chavachol Setthaudom[SUP] 3 [/SUP], Pattaraphorn Phornkittikorn[SUP] 4 [/SUP], Pongsathon Chaumdee[SUP] 4 [/SUP], Somsak Prasongtanakij[SUP] 5 [/SUP], Supanart Srisala[SUP] 5 [/SUP], Kumthorn Malathum[SUP] 1 [/SUP], Sarinya Boongird[SUP] 6 [/SUP], Arkom Nongnuch[SUP] 6 [/SUP], Montira Assanatham[SUP] 6 [/SUP], Laor Nakgul[SUP] 1 [/SUP], Nutaporn Sanmeema[SUP] 1 [/SUP], Angsana Phuphuakrat[SUP] 1 [/SUP], Sasisopin Kiertiburanakul[SUP] 1 [/SUP], Ramathibodi Transplant Infectious Diseases (RTID) Study Group
Affiliations
Abstract
Immunogenicity following an additional dose of Coronavirus disease 2019 (COVID-19) vaccine was investigated in an extended primary series among kidney transplant (KT) recipients. Eighty-five KT participants were randomized to receive either an mRNA (M group; n=43) or viral vector (V group; n=42) vaccine. Among them, 62% were male, with a median (IQR) age of 50(43-59) years and post-transplantation duration of 46(26-82) months. At 2 weeks post-additional dose, there was no difference in the seroconversion rate between the M and V groups (70%vs.65%, p=0.63). A median (IQR) of anti-RBD antibody level was not statistically different between the M group compared with the V group (51.8[5.1-591] vs. 28.5[2.9-119.3] BAU/ml, p=0.18). Furthermore, the percentage of participants with positive SARS-CoV-2 surrogate virus neutralization test results was not statistically different between groups (20%vs.15%, p=0.40). S1-specific T-cell and RBD-specific B-cell responses were also comparable between the M and V groups (230[41-420] vs. 268[118-510], p=0.65 and 2[0-10] vs. 2[0-13] spot-forming units/10[SUP]6[/SUP] peripheral blood mononuclear cells, p=0.60). In conclusion, compared with an additional dose of viral vector COVID-19 vaccine, a dose of mRNA COVID-19 vaccine did not elicit significantly different responses in KT recipients, regarding either humoral or cell-mediated immunity.
Keywords: BNT162b2; ChAdOx1 nCoV-19; SARS-CoV-2; booster; immunization; immunocompromised; mRNA-1273.
. 2022 Jul 16.
doi: 10.1111/ajt.17151. Online ahead of print.
An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: a randomized controlled trial (CVIM 4 study)
Jackrapong Bruminhent[SUP] 1 2 [/SUP], Chavachol Setthaudom[SUP] 3 [/SUP], Pattaraphorn Phornkittikorn[SUP] 4 [/SUP], Pongsathon Chaumdee[SUP] 4 [/SUP], Somsak Prasongtanakij[SUP] 5 [/SUP], Supanart Srisala[SUP] 5 [/SUP], Kumthorn Malathum[SUP] 1 [/SUP], Sarinya Boongird[SUP] 6 [/SUP], Arkom Nongnuch[SUP] 6 [/SUP], Montira Assanatham[SUP] 6 [/SUP], Laor Nakgul[SUP] 1 [/SUP], Nutaporn Sanmeema[SUP] 1 [/SUP], Angsana Phuphuakrat[SUP] 1 [/SUP], Sasisopin Kiertiburanakul[SUP] 1 [/SUP], Ramathibodi Transplant Infectious Diseases (RTID) Study Group
Affiliations
- PMID: 35841235
- DOI: 10.1111/ajt.17151
Abstract
Immunogenicity following an additional dose of Coronavirus disease 2019 (COVID-19) vaccine was investigated in an extended primary series among kidney transplant (KT) recipients. Eighty-five KT participants were randomized to receive either an mRNA (M group; n=43) or viral vector (V group; n=42) vaccine. Among them, 62% were male, with a median (IQR) age of 50(43-59) years and post-transplantation duration of 46(26-82) months. At 2 weeks post-additional dose, there was no difference in the seroconversion rate between the M and V groups (70%vs.65%, p=0.63). A median (IQR) of anti-RBD antibody level was not statistically different between the M group compared with the V group (51.8[5.1-591] vs. 28.5[2.9-119.3] BAU/ml, p=0.18). Furthermore, the percentage of participants with positive SARS-CoV-2 surrogate virus neutralization test results was not statistically different between groups (20%vs.15%, p=0.40). S1-specific T-cell and RBD-specific B-cell responses were also comparable between the M and V groups (230[41-420] vs. 268[118-510], p=0.65 and 2[0-10] vs. 2[0-13] spot-forming units/10[SUP]6[/SUP] peripheral blood mononuclear cells, p=0.60). In conclusion, compared with an additional dose of viral vector COVID-19 vaccine, a dose of mRNA COVID-19 vaccine did not elicit significantly different responses in KT recipients, regarding either humoral or cell-mediated immunity.
Keywords: BNT162b2; ChAdOx1 nCoV-19; SARS-CoV-2; booster; immunization; immunocompromised; mRNA-1273.